Services / Cancer Care / Research / Clinical Trials /

Clinical Trial

« Back to List

Iressa Clinical Access Program

Posted by: Asheesh Lal, MD, Principal Investigator | Posted Date: June 09, 2011

Details: An Open Label, Multi-Center IRESSA, Clinical Access Program of Gefitinib 250 mg (Iressa) for the continued treatment of patients in the United States who are currently benefiting or have benefited from Gefitinib treatment

This clinical trial is being offered at the following location:Lexington Oncology

Bookmark and Share